Cellebrite Di Ltd. (CLBT) intrinsic value & 10-year financials
Cellebrite Di Ltd. (CLBT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 18.5% a year to $475.7M, with an average return on invested capital of 318.3%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $475.7M
- Revenue growth (8-yr CAGR)
- 18.5%
- ROIC (10-yr avg)
- 318.3%
- Free cash flow (FY2025)
- $160.3M
CLBT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $475.7M | $78.3M | $0.31 | $160.3M | 14.0% | 21.7% |
| FY2024 | $401.2M | -$283.0M | -$1.35 | $123.6M | 14.2% | 2250.6% |
| FY2023 | $325.1M | -$81.1M | -$0.43 | $96.8M | 10.2% | -44.4% |
| FY2022 | $270.7M | $120.8M | $0.59 | $13.7M | 0.4% | -0.9% |
| FY2021 | $246.2M | $71.4M | $0.44 | $30.9M | 5.6% | -5.5% |
| FY2020 | $194.9M | $5.8M | -$0.08 | $60.3M | 4.7% | 7.6% |
| FY2019 | $171.9M | -$1.9M | -$0.08 | $9.9M | -0.9% | -1.2% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cellebrite DI Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cellebrite DI Ltd. has historically struggled to out-earn its cost of capital, averaging just -1.3% ROIC.
Cellebrite DI Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cellebrite DI Ltd. is modeled at -8.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.21 per share.